In situ methods of inducing of immune response
AssigneeAtossa Therapeutics, Inc.
InventorSteven C. Quay
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to intraductal methods and compositions for inducing immune response in subjects having breast cancer. The intraductally administered compositions comprise one or more bioactive agents capable of inducing in situ maturation of antigen presenting cells and migration of mature antigen presenting cells to lymph nodes. The intraductal methods and compositions induce the activation of effector immune cells, and augment tumor cell death.
Claims50
A method of inducing immune response in a subject, comprising administering intraductally to a breast milk duct of the subject an effective amount of a composition comprising one or more bioactive agents, wherein the composition induces in situ maturation of antigen presenting cells.
The method of any one of the preceding claims, wherein the antigen presenting cell is a dendritic cell.
The method of any one of the preceding claims, wherein the composition induces migration of the antigen presenting cell to a lymph node in the subject.
The method of any one of the preceding claims, wherein the immune response comprises activation of effector T-cells, effector NK cells, effector B-cells, or a combination thereof.
The method of any one of the preceding claims, wherein the immune response comprises antitumor T-cell effector response, NK cell effector response, or B-cell anti-tumor effector response, or a combination thereof.
The method of any one of the preceding claims wherein the effector T-cells comprise cytotoxic CD8+ T-cells, CD4+ Th1 cells, memory T-cells, Tfh cells, or a combination thereof.
The method of any one of the preceding claims, wherein the immune response comprises reduction in immunosuppression.
The method of any one of the preceding claims, wherein the tumor size of the subject is reduced.
The method of any one of the preceding claims, wherein the composition further comprises an effective amount of a bioactive agent capable of inducing recruitment of inbound antigen presenting cells to the milk duct or breast tissue of the subject selected from the group consisting of cytokines and chemokines (such as IL-1β, MCP-1, RANTES, MIP-1α, MIP-1β, IL-8, C1q, CCL1 (CCR1 ligand), CCL2 (CCR2 ligand), CCLS (CCR5 ligand), CCL20 (CCR6 ligand), CXCL3 (CXCR3 ligand), CXCL4 (CXCR4 ligand) and CXCL1 (CXCR1 ligand)), DAMPs such as HMGB1, and TLR agonists (like TLR3 agonists (such as Poly (I:C), polyadenosine-polyuridylic acid (poly AU) Ampligen (polyI:polyC (12)U and Polyinosinic-Polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose (Poly-ICLC), TLR4 agonists such as glucanopynosyl lipoid A (G100), GSK1795091, Monophosphoryl lipid A (MPL) and MPL-based agonists such as aminoalkyl glucosaminide phosphates (AGPs), lipopolysaccharides (LPS) and opioids such as methadone, morphine-3-glucuronide, TLR7 agonists and TLR8 agonists such as imidazoquinolines (Imiquimod and Resiquimod (R848)), TLR9 agonists such as (CpG-ODNs such as PF-3512676, and the like).
The method of any one of the preceding claims, wherein the Type-1 polarizing agent or bioactive agent capable of inducing recruitment of inbound antigen presenting cells or both, is a TLR3 agonist, TLR4 agonist, TLR7 agonist, TLR8 agonist or TLR9 agonist.
The method of any one of the preceding claims, wherein the composition further comprises an effective amount of a repolarizing agent capable of repolarizing an M2-DC to Type-1 polarized DC (DC1) selected from the group consisting of fenretinide (4-hydroxy(phenyl)retinamide, 4-HPR);
- IL-12;
- IFNγ, miR127, miR155, and miR223, ferumoxytol, inhibitors of:
- CSF-1, CSF-1R, IL-10, IL-10R, TGFβ, Arginase 1 (Arg1), M2 macrophage scavenger receptors (such as A, B, MARCO), histone deacetylase (HDACi), DICER, IRF4/STAT4/STAT6 signaling pathway;
- IL-4, IL-13, IL-17, PPARγ, KLF4, KLF6, miRNA-146 family members such as (miRNA-146a), let7 family members (such as let-7c), miRNA-9, miRNA-21, miRNA-47, miRNA-187, CCR-CC12 axis signaling, CCL2/MCP-1, placental growth factor (PlGF) (HRG) and C/EBPβ (PI3Kγ deletion), AMPKα1 (metformin), p50-p50 NFκB, NADPH oxidase (NOX) (NOX 1 and NOX 2) such as GKT137831, Rbpj, Notch signaling pathway;
- activators/agonists of CD40 and CD40L, IRF1, IRF5, STAT1 (such as IFNγ, vadimezan (DMXAA)) and STAT3, nuclear factor kappa B activators, toll-like receptor (TLR) agonists of TLR3, TLR4, TLR7, TLR8, and TLR9 such as Imiquimod, synthetic unmethylated cytosine-guanine (CpG) oligodeoxinucleotides (CpG-ODNs), (poly I:C), C792, lefitolimod (MGN1703), SD-101 (Dynavax), SD-101, IMO-2125;
- p65-p50 NFκB, MyD88, miR127, miR155, and miR223, or a combination thereof.
The method of any one of the preceding claims, wherein the composition further comprises an effective amount of a blockading agent capable of reducing or preventing DC-to-macrophage shift, wherein the blockading agent is selected from a group consisting of CSF-1 inhibitors, CSF-1R inhibitors, MCP-1 inhibitors, IL-4 inhibitors (such as pascolizumab, pitakinra and dupilumab), IL-10 inhibitors, IL-13 inhibitors (such as anrukinzumab, lebrikizunab and tralokinumab), IL-4/IL-13 dual inhibitors such as duplimab, prostanoid inhibitors (such inhibitors of PGE3), STAT3 inhibitors (such as sorafenib, sunitinib, WP1066, and resveratrol), and STATE inhibitors (such as fenretinide (4-HPR), leflunomid, TMX264, and AS1217499), or a combination thereof.
The method of any one of the preceding claims, wherein the method further comprises administering to the subject an effective amount of an additional therapeutic agent selected from the group consisting of anti-hormonals (e.g., anti-estrogen or anti-estrogen receptor, such as tamoxifen, cis-tamoxifen, endoxifen, desmethyltamoxifen, lasofoxifene, raloxifene, benzothiophene, bazedofoxifene, arzoxifene, miproxifene, levormeloxifene, droloxifene, clomifene, idoxifene, toremifene, EM652 and ERA-923, fulvestrant, ARN-810, or CH498, anastrozole, exemestane and letrozole), steroids, anthracyclines, thyroid hormone replacement drugs, cytotoxic agents such as alkylating agents (such as temozolomide and cyclophosphamide), anthracyclines (such as doxorubicin, pegylated liposomal doxorubicin, epirubicin, idarubicin, and the like), anthracenediones such as mitoxantrone, platinum drugs (such as cisplatin, carboplatin, oxaliplatin, ormaplatin, enloplatin, and the like), taxanes (such as paclitaxel), antimitotic drugs, bleomycin, bortezomib, patupilone, calreticulin, broad spectrum cell death agents such as glossypol, tea phenols such as Epigallocatechin-3-Gallate, 7-Bromoindirubin-3′-oxime (7BIO)-, oncogenic RAS, macrolides, Berberine (an isoquinoline alkaloid derived from plants), UMI-77, triptolide and selinexor, broad spectrum inhibitor of extracellular nucleotidases, such as ARL67156, temozolomide cyclophosphamide, mafosfamide, doxorubicin, epirubincin, idarubicin, mitoxantrone, oxaliplatin, paclitaxel, bleomycin, bortezomib, oncolytic viruses, patupilone, Tyrphostin AG 490, a Janus Activated Kinase 2/signal trasducer and activator of transcription-3 (JAK2/STAT3) inhibitor, DNA hypomethylating agents (such as azacitidine or decitabine), thymidylate-targeted drugs (such as docetaxel, gemcitabine), trastuzumab, ado-trastuzumab emtansine, pertuzumab, abemaciclib, palbociclib, anti-IL-10 inhibitors, anti-TGF-β inhibitors, checkpoint inhibitors (like PD-1 inhibitors such as anti-PD-1 antibodies (e.g., Nivolumab), PD-1L inhibitors such as anti-PD-1L (e.g., atezolizumab (MPDL3280), Avelumab (MSB0010718C), Durvalumab, MDX-1105), CTLA-4 inhibitors such as anti-CTLA4 antibodies (e.g., Ipilimumab), LAG-3 inhibitors such as anti-LAG-3 antibodies (e.g., IMP321, BMS-986016 and GSK2831781), OX-40 agonists such as MOXR0916, PF-04518600, MEDI0562, MEDI6469, and MEDI6383, TIM inhibitors, IDO inhibitors), CCR4 inhibitors, FoxP3 inhibitors, cell therapy such as Chimeric Antigen Receptor/T-cell (CAR-T) therapies, and other adoptive cell therapies, or a combination thereof.
The method of any one of the preceding claims, wherein the subject is intraductally administered an effective amount of a composition comprising a TLR9 agonist and an OX-40 agonist.
A method of inducing migration of antigen presenting cells in a subject comprising administering intraductally to a breast milk duct of the subject an effective amount of a composition comprising one or more bioactive agents, wherein at least one bioactive agent comprised in the composition is capable of inducing migration of the antigen presenting cells to a lymph node in the subject.
A method for inducing or augmenting immunological cell death in breast tumor cells of a subject, comprising administering to the subject an effective amount of a cytotoxic agent, and administering intraductally an effective amount of a composition comprising one or more bioactive agents.
The method of any of the preceding claims, wherein the composition is intraductally administered in a single dose or multiple doses.
The method of any one of the preceding claims, wherein the composition is administered daily, several times a day (twice, thrice, four times and the like), alternate days, every 2 days, 3 days, 5 days, 7 days, 14 days, 15 days, every 3 weeks, 28 days, monthly, quarterly, 6 monthly, and annually.
The composition of any one of the preceding claims, further comprising an imaging agent, a dye or a contrasting agent selected from the groups consisting of gadolinium chelates, superparamagnetic iron oxide nanoparticles (SPION), 19F perfluorocarbon nanoparticles, and other magnetic reporter genes, such as metalloprotein-based MM probes.
The composition of any one of the preceding claims, further comprising a pharmaceutically acceptable carrier.
The composition of any one of the preceding claims, wherein the composition is formulated as a liposome, a nanoparticle, a microparticle, a microsphere, a nanocapsule, a nanosphere, a lipid particle, a vesicle, or a micelle.
The composition of any one of the preceding claims, wherein the one or more bioactive agent is comprised in a liposome, a microparticle, a microsphere, a nanocapsule, a nanoparticle, a nanosphere, a lipid particle, a vesicle, or a micelle.
The composition of any one of the preceding claims, wherein the one or more bioactive agent is comprised on a liposome, a microparticle, a microsphere, a nanocapsule, a nanoparticle, a nanosphere, a lipid particle, a vesicle, or a micelle.
The composition of any one of the preceding claims, wherein the nanoparticle is a lipid nanoparticle.
The composition of any one of the preceding claims, wherein the nanoparticle is further coated with a cell targeting agent.
Dependencies are inferred from the claim text.